Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Amarin Corporation plcNASDAQ: AMRN
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items declines year over year
Q1 FY2026 other non-cash items of $532K (cash outflow) fell 56.3% year over year, ahead of the -431.8% change in trailing-twelve-month other non-cash items. Sequentially, it fell 97.6% from the prior quarter.
Context
- Other non-cash items amounted to 1.7% of revenue in FY2025, down 0.8 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -56.3% holds above the trailing-twelve-month pace of -431.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- (3.71M) USD
- Year-over-year change
- +35.3%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.71M) | +35.3% |
| FY2024 | 2024-12-31 | (5.73M) | -147.8% |
| FY2023 | 2023-12-31 | 12M | -55.0% |
| FY2022 | 2022-12-31 | 26.67M | -31.4% |
| FY2021 | 2021-12-31 | 38.86M | — |
Other Non-Cash Items vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -431.8% is the lowest of 10, against a peer median of +30.1%.
- Other non-cash items amounts to 10.6% of revenue for AMRN, versus a peer median of 3900.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $70.22M USD | — | — | 7620.1% | |
| LTM Mar 2026 | $67.8M USD | -43.9% | +0.8% | 218706.5% | |
| LTM Mar 2026 | $35.13M USD | +6869.2% | +175.6% | 914.2% | |
| LTM Mar 2026 | $22.77M USD | -431.8% | — | 10.6% | |
| LTM Mar 2026 | $19.72M USD | +30.1% | — | 29.0% | |
| LTM Mar 2026 | $13.99M USD | +178.1% | +521.5% | — | |
| LTM Mar 2026 | $4.01M USD | +59.1% | +61.6% | — | |
| LTM Mar 2026 | $2.48M USD | +254.0% | +43.3% | 6886.1% | |
| LTM Mar 2026 | $1.33M USD | -72.8% | -30.0% | — | |
| LTM Dec 2025 | CHF 606.88K CHF | -74.7% | — | 17.0% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $7K USD | -99.4% | — | — |
| Peer median (excluding AMRN) | — | +30.1% | +52.5% | 3900.2% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.73M | (105.74M) | (59.34M) | (82.18M) | (38.8M) |
| Depreciation & Amortization | 2.86M | 3.09M | 2.98M | 3.01M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 17.71M | 13.94M |
| Change in Working Capital | (115.98M) | (104.01M) | 51.27M | 36.17M | 32.28M |
| Accounts Receivables | (8.34M) | 32.98M | (2.33M) | 11.22M | (3.83M) |
| Inventory | (167.05M) | (36.4M) | 56.34M | 105.44M | 34.96M |
| Accounts Payables | 51.51M | (102.67M) | (164.64K) | (77.02M) | 14.54M |
| Other Working Capital | 7.9M | 2.07M | (2.56M) | (3.5M) | (13.39M) |
| Other Non-Cash Items | 38.86M | 26.67M | 12M | (5.73M) | (3.71M) |
| Operating Cash Flow | (66.53M) | (179.98M) | 6.91M | (31.03M) | 6.74M |
| Capital Expenditures | 2 | (2) | (24.1K) | 2 | 0 |
| Acquisitions (Net) | 4K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (290.16M) | (81.58M) | (215.93M) | (278.78M) | (200.94M) |
| Sales of Investments | 394.25M | 257.36M | 190.84M | 232.8M | 209.79M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 104.09M | 175.18M | (25.62M) | (45.98M) | 8.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.57M | 664.59K | 2.22M | 131.06K | 140.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.64M) | (1.04M) | (1.99M) | (1.57M) | (2.18M) |
| Financing Cash Flow | (5.07M) | (378.77K) | 230.89K | (1.44M) | (2.04M) |
| Effect of Forex Changes | 3.87K | (3.2K) | 71.37K | 33.01K | (31.6K) |
| Net Change in Cash | 32.49M | (5.18M) | (18.41M) | (78.44M) | 13.52M |
| Free Cash Flow | (66.53M) | (179.98M) | 6.88M | (31.02M) | 6.74M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.